|
Ouabain
drug data and news
Ouabain drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
| Generic name |
Ouabain
|
| Brand Names/Synonyms |
Acocantherin; Astrobain; G-Strophanthin; G-Strophicor; Gratibain; Gratus Strophanthin; Kombetin; Ouabagenin L-Rhamnoside; Ouabain; Ouabain Octahydrate; Ouabain, Octahydrate; Ouabaine; Purostrophan; Rectobaina; Solufantina; Strodival; Strophalen; Strophanthin G; Strophanthin-G; Strophoperm; Strophosan; Uabaina; Uabanin |
| Indication |
For the treatment of atrial fibrillation and flutter and heart failure |
|
Sponsored links
|
|
Description |
Not Available |
| Pharmacology |
Ouabain, a cardiac glycoside similar to digitoxin, is used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation. |
| Mechanism Of Action |
Ouabain inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Ouabain also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential. |
Ouabain News
(When available) |
[an error occurred while processing this directive] |
| Dosage Forms |
Not Available |
| Drug_Category |
Cardiotonic Agents; |
| Absorption |
Not Available |
| Interactions |
Not Available |
| Toxicity |
Not Available |
| Organisms Affected |
Humans and other mammals |
| Chemical IUPAC Name |
4-[1,5,11,14-tetrahydroxy-10-(hydroxymethyl)-13-methyl-3-(3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl)oxy-2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17-hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl]-5H-furan-2-one |
| Chemical Formula |
C29H44O12 |
| Molecular Weight |
584.652 g/mol |
| Smiles String |
CC1C(C(C(C(O1)OC2CC(C3(C4C(CCC3(C2)O)C5(CCC(C5(CC4O)C)C6=CC(=O)OC6)O)CO)O)O)O)O |
| Melting Point |
200 °C |
| Water Solubility |
1.03E+004 mg/L |
| State |
Solid |
| LogP/Hphobicity |
-2.038 |
| Isoelectric Point |
Not Available |
| Biotransformation |
Not Available |
| Half Life |
Not Available |
| Protein Binding [%] |
60% |
| RxList Link |
Not Available>RXlist |
|
Sponsored links
|
|
| Drug Reference |
Not Available |
| Drug Type |
Approved Drug |
| Accession No |
APRD00135 |
| CAS Registry Number |
630-60-4 |
| KEGG Compound ID |
C01443 |
| PubChem ID |
SID:4621 |
| PharmGKB ID |
Not Available |
| SwissProt ID |
Not Available |
| GenBank ID |
Not Available |
| Drug ID Number [DIN] |
Not Available
|
|
|
